Tacrolimus effect on rosacea.

Abstract

Twenty-four patients with erythrotelangiectatic or papulopustular rosacea were treated with 0.1% tacrolimus topical ointment in a 12-week open-label trial. Erythema was significantly improved in both rosacea subtypes (P<.05). There was no decrease in the number of papulopustular lesions. Side effects were consistent with those on the tacrolimus topical ointment labeling.

• Authors: Joel T M Bamford, Barbara A Elliott, Irina V Haller
• Journal: Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 50 Issue 1 Pg. 107-8 (Jan 2004) ISSN: 0190-9622 [Print] United States
• PMID: 14699377 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Immunosuppressive Agents
• Tacrolimus

Topics

• Female
• Humans
• Immunosuppressive Agents (therapeutic use)
• Male
• Rosacea (drug therapy)
• Tacrolimus (therapeutic use)